Aachen, February 10, 2016 – The Grünenthal Group announced today the completion and inauguration of its new research building on the Grünenthal Campus in Aachen. It will accommodate room for 150 employees working in research and development. Thus Grünenthal again commits to its headquarters in Aachen and to researching and developing of innovative medicines to the benefits of patients. The annual Research & Development expenditures of the group have constantly been well above the pharmaceutical industry's average for years in relation to sales. The Grünenthal Campus in Aachen has been continuously enlarged since 2011. In the last five years, the company has invested 131 million Euros for real estate, buildings and production sites.
"The new building is a significant investment in the company's headquarters in Aachen and emphasizes Grünenthal's strong commitment into our long-term Research & Development strategy focusing on innovation", Prof. Eric-Paul Pâques, Chief Executive Officer Grünenthal Group explains. "We are convinced of our expertise in researching and developing innovative products which will deliver true benefits to the patients – this investment is a logical consequence of this principle".
"The key objective for the set-up and the design of our new research building was to develop a state-of-the-art and inspiring working environment which shall motivate cross-functional information sharing and team work of our staff", Dr. Klaus-Dieter Langner, Chief Scientific Officer Grünenthal Group commented.
With a construction period of only two years, the new research building offers research space of 12,500 m². In total, three laboratory floors, with corresponding office space, meeting rooms and support areas have been installed. By the end of 2015, all future residents took up their regular functions.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Australia, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,300 employees are working for the Grünenthal Group worldwide. In 2014, Grünenthal achieved revenues of € 1.154 bn. More information:www.grunenthal.com.